Patent application EP16002117A (EP), filed 2016-09-30
Publication number: EP3150223A1
Title: REPLICATION-COMPETENT VSV-HIV ENV VACCINES
Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
IPC codes: A61K  39/    21            A I
C12N   7/    00            A I
Claims: number: 1
text: A recombinant vesicular stomatitis virus (VSV) vector wherein the gene encoding the VSV surface glycoprotein G (VSV G) is functionally replaced by functional clade A HIV Env BG505.
number: 2
text: The vector of claim 1 wherein the vector contains and expresses a nucleic acid sequence encoding an amino acid sequence of an Env.BG505 immunogen encoded by the VSVΔG-Env.BG505.
number: 3
text: The vector of claim 1, wherein the amino acid sequence of an Env.BG505 immunogen encoded by the VSVΔG-Env.BG505 is SEQ ID NO: 2.
number: 4
text: The vector of claim 1 wherein the vector comprises the sequence of a VSVΔG-Env.BG505 genomic clone.
number: 5
text: The vector of claim 4, wherein the sequence of a VSVΔG-Env.BG505 genomic clone is SEQ ID NO: 1.
number: 6
text: The vector of any one of claims 1-5 wherein the HIV Env is recognized by antibodies PG9, PG16, 2G12, b12, 2F5, 4E10 or Z13, or broad potent neutralizing trimer-specific antibodies.
number: 7
text: A vaccine comprising the vector of any one of claims 1-6.
number: 8
text: The vaccine of claim 7, wherein the vaccine is an intramuscular or mucosal vaccine.
number: 9
text: The vaccine of claim 7 or 8, wherein the vaccine is a G-pseudotyped VSVΔG-Env.BG505 vaccine.
number: 10
text: A method of producing an immune response or eliciting an immune response against HIV comprising administering to a mammal a VSV vector wherein the gene encoding the VSV G is functionally replaced by a HIV Env.
number: 11
text: The method of claim 10, wherein the HIV Env is a functional clade functional clade A, Clade B, Clade C or Clade E Env.
number: 12
text: The method of claim 10, wherein the HIV Env is recognized by a PG9, PG16, 2G12, b 12, 2F5, 4E10, Z13 or a broadly neutralizing trimer-specific antibody.
number: 13
text: The method of claim 10, wherein the HIV Env is HIV Env BG505.
number: 14
text: The method of claim 10, wherein a dose is about 1x10<4> to 2x10<8> pfu per ml.
number: 15
text: The method of claim 10, wherein the vector is administered to a nasal and/or oral cavity.
number: 16
text: The method of claim 15, wherein a dose of 1x10<8> pfu per ml is administered to each cavity.
number: 17
text: The method of claim 10, wherein the vector is administered over a vaccination schedule from about 0 to 29 weeks.
number: 18
text: The method of claim 17, wherein the vaccination schedule is at 0, 4 and 29 weeks.
number: 19
text: The method of claim 10, wherein the vector is administered as a single dose.
Office action: search_report, dated 2017-04-05
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: US4556556A
ref_type: patent
severity: background
ref_id: US7341731B2
ref_type: patent
severity: background
ref_id: US7335364B2
ref_type: patent
severity: background
ref_id: US7329807B2
ref_type: patent
severity: background
ref_id: US7323553B2
ref_type: patent
severity: background
ref_id: US7320859B2
ref_type: patent
severity: background
ref_id: US7393949B1
ref_type: patent
severity: background
ref_id: US7374877B2
ref_type: patent
severity: background
ref_id: US5223423A
ref_type: patent
severity: background
ref_id: US5204259A
ref_type: patent
severity: background
ref_id: US5144019A
ref_type: patent
severity: background
ref_id: US5051496A
ref_type: patent
severity: background
ref_id: US4942122A
ref_type: patent
severity: background
ref_id: US6949337B2
ref_type: patent
severity: background
ref_id: US6900010B2
ref_type: patent
severity: background
ref_id: US6821744B2
ref_type: patent
severity: background
ref_id: US6768004B2
ref_type: patent
severity: background
ref_id: US6613743B2
ref_type: patent
severity: background
ref_id: US6534312B1
ref_type: patent
severity: background
ref_id: US6511830B1
ref_type: patent
severity: background
ref_id: US6489131B1
ref_type: patent
severity: background
ref_id: US6242197B1
ref_type: patent
severity: background
ref_id: US6114143A
ref_type: patent
severity: background
ref_id: US6074646A
ref_type: patent
severity: background
ref_id: US6063564A
ref_type: patent
severity: background
ref_id: US6060254A
ref_type: patent
severity: background
ref_id: US5919457A
ref_type: patent
severity: background
ref_id: US5916806A
ref_type: patent
severity: background
ref_id: US5871732A
ref_type: patent
severity: background
ref_id: US5824304A
ref_type: patent
severity: background
ref_id: US5773247A
ref_type: patent
severity: background
ref_id: US5736320A
ref_type: patent
severity: background
ref_id: US5637455A
ref_type: patent
severity: background
ref_id: US5587285A
ref_type: patent
severity: background
ref_id: US5514541A
ref_type: patent
severity: background
ref_id: US5317009A
ref_type: patent
severity: background
ref_id: US4983529A
ref_type: patent
severity: background
ref_id: US4886742A
ref_type: patent
severity: background
ref_id: US4870003A
ref_type: patent
severity: background
ref_id: US4795739A
ref_type: patent
severity: background
ref_id: US7074556B2
ref_type: patent
severity: background
ref_id: US7074554B2
ref_type: patent
severity: background
ref_id: US7070787B2
ref_type: patent
severity: background
ref_id: US7060273B2
ref_type: patent
severity: background
ref_id: US7045130B1
ref_type: patent
severity: background
ref_id: US7033593B2
ref_type: patent
severity: background
ref_id: USRE39057E
ref_type: patent
severity: background
ref_id: US7468274B2
ref_type: patent
severity: background
ref_id: US7419829B2
ref_type: patent
severity: background
ref_id: US7419674B2
ref_type: patent
severity: background
ref_id: US7344838B2
ref_type: patent
severity: background
ref_id: US4396628A
ref_type: patent
severity: background
ref_id: US6693086B1
ref_type: patent
severity: background
ref_id: US5057540A
ref_type: patent
severity: background
ref_id: US5650398A
ref_type: patent
severity: background
ref_id: US6524584B2
ref_type: patent
severity: background
ref_id: US6645495B1
ref_type: patent
severity: background
ref_id: US4689338A
ref_type: patent
severity: background
ref_id: US5238944A
ref_type: patent
severity: background
ref_id: WO0195919A2
ref_type: patent
severity: background
ref_id: WO03063899A2
ref_type: patent
severity: background
ref_id: WO9620013A1
ref_type: patent
severity: background
ref_id: WO0147955A2
ref_type: patent
severity: background
ref_id: US2004037699W
ref_type: patent
severity: background
ref_id: - ABBAS ET AL.: "Cellular and Molecular Immunology", 2000, W.B. SAUNDERS COMPANY, pages: 454
ref_type: npl
severity: background
ref_id: - WYATT; SODROSKI, SCIENCE, vol. 280, no. 5371, 19 June 1998 (1998-06-19), pages 1884 - 8
ref_type: npl
severity: background
ref_id: - BURTON ET AL., NAT IMMUNOL., vol. 5, no. 3, March 2004 (2004-03-01), pages 233 - 6
ref_type: npl
severity: background
ref_id: - PARREN; BURTON, ADV IMMUNOL., vol. 77, 2001, pages 195 - 262
ref_type: npl
severity: background
ref_id: - JOHNSON; DESROSIERS, ANNU REV MED., vol. 53, 2002, pages 499 - 518
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - ANDRE ET AL., J. VIROL., vol. 72, 1998, pages 1497 - 1503
ref_type: npl
severity: background
ref_id: - RABINOVICH ET AL., PLOS ONE, vol. 9, no. 9, 12 September 2014 (2014-09-12), pages E106597
ref_type: npl
severity: background
ref_id: - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
ref_type: npl
severity: background
ref_id: - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
ref_type: npl
severity: background
ref_id: - MYERS; MILLER, CABIOS, vol. 4, 1988, pages 11 - 17
ref_type: npl
severity: background
ref_id: - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 - 2448
ref_type: npl
severity: background
ref_id: - ALTSCHUL; GISH: "Methods in Enzymology", vol. 266, 1996, article "Local alignment statistics", pages: 460 - 480
ref_type: npl
severity: background
ref_id: - ALTSCHUL ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410
ref_type: npl
severity: background
ref_id: - GISH; STATES, NATURE GENETICS, vol. 3, 1993, pages 266 - 272
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989
ref_type: npl
severity: background
ref_id: - HOFFENBERG ET AL., J. VIROL., vol. 87, no. 10, May 2013 (2013-05-01), pages 5372 - 5383
ref_type: npl
severity: background
ref_id: - "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING COMPANY
ref_type: npl
severity: background
ref_id: - CHUANG, T.H. ET AL., J. LEUK. BIOL., vol. 71, no. 3, 2002, pages 538 - 44
ref_type: npl
severity: background
ref_id: - AHMAD-NEJAD, P. ET AL., EUR. J. IMMUNOL., vol. 32, no. 7, 2002, pages 1958 - 68
ref_type: npl
severity: background
ref_id: - SCHELLACK, C. ET AL., PROCEEDINGS OF THE 34TH ANNUAL MEETING OF THE GERMAN SOCIETY OF IMMUNOLOGY, 2003
ref_type: npl
severity: background
ref_id: - LINGNAU, K. ET AL., VACCINE, vol. 20, no. 29-30, 2002, pages 3498 - 508
ref_type: npl
severity: background
ref_id: - MCSORLEY, S.J. ET AL., J. IMMUNOL., vol. 169, no. 7, 2002, pages 3914 - 9
ref_type: npl
severity: background
ref_id: - VEAZEY, R.S. ET AL., J. EXP. MED., vol. 198, 2003, pages 1551 - 1562
ref_type: npl
severity: background
ref_id: - MOWAT, A.M. ET AL., J. IMMUNOL., vol. 167, no. 6, 2001, pages 3398 - 405
ref_type: npl
severity: background
ref_id: - ALLCOCK, H.R., APP. ORGANOMETALLIC CHEM., vol. 12, no. 10-11, 1998, pages 659 - 666
ref_type: npl
severity: background
ref_id: - PAYNE, L.G. ET AL., PHARM. BIOTECHNOL., vol. 6, 1995, pages 473 - 93
ref_type: npl
severity: background
ref_id: - BOYER ET AL., J. LIPOSOME RES., vol. 121, 2002, pages 137 - 142
ref_type: npl
severity: background
ref_id: - GREEN, T.D. ET AL., J. VIROL., vol. 77, no. 3, 2003, pages 2046 - 2055
ref_type: npl
severity: background
ref_id: - BAROUCH ET AL., SCIENCE, vol. 290, 2000, pages 486 - 492
ref_type: npl
severity: background
ref_id: - "New Trends and Developments in Vaccines", 1978, UNIVERSITY PARK PRESS
ref_type: npl
severity: background
ref_id: - "Remington's Pharmaceutical Sciences"
ref_type: npl
severity: background
ref_id: - ED HARLOW; DAVID LANE: "Antibodies: A Laboratory Manual"
ref_type: npl
severity: background
ref_id: - WATANABE, MOL. REPROD. DEV., vol. 38, 1994, pages 268 - 274
ref_type: npl
severity: background
ref_id: - ROBINSON ET AL., VACCINE, vol. 11, 1993, pages 957 - 960
ref_type: npl
severity: background
ref_id: - HOFFMAN ET AL., VACCINE, vol. 12, 1994, pages 1529 - 1533
ref_type: npl
severity: background
ref_id: - XIANG ET AL., VIROLOGY, vol. 199, 1994, pages 132 - 140
ref_type: npl
severity: background
ref_id: - WEBSTER ET AL., VACCINE, vol. 12, 1994, pages 1495 - 1498
ref_type: npl
severity: background
ref_id: - DAVIS ET AL., VACCINE, vol. 12, 1994, pages 1503 - 1509
ref_type: npl
severity: background
ref_id: - DAVIS ET AL., HUM. MOL. GEN., vol. 2, 1993, pages 1847 - 1851
ref_type: npl
severity: background
ref_id: - JOHNSTON ET AL., METH. CELL BIOL., vol. 43, 1994, pages 353 - 365
ref_type: npl
severity: background
ref_id: - ROSE NF; ROBERTS A; BUONOCORE L; ROSE JK: "Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1", J VIROL., vol. 74, no. 23, December 2000 (2000-12-01), pages 10903 - 10, XP008148240, DOI: doi:10.1128/JVI.74.23.10903-10910.2000
ref_type: npl
severity: background
ref_id: - LAWSON ND; STILLMAN EA; WHITT MA; ROSE JK: "Recombinant vesicular stomatitis viruses from DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, no. 10, 1995, pages 4477 - 81, XP002910311, DOI: doi:10.1073/pnas.92.10.4477
ref_type: npl
severity: background
ref_id: - CLARKE DK; NASAR F; CHONG S; JOHNSON JE; COLEMAN JW; LEE M; WITKO SE; KOTASH CS; ABDULLAH R; MEGATI S: "Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates", J VIROL., vol. 88, no. 12, 2014, pages 6690 - 701, XP055343413, DOI: doi:10.1128/JVI.03441-13
ref_type: npl
severity: background
ref_id: - JONES SM; FELDMANN H; STROHER U; GEISBERT JB; FERNANDO L; GROLLA A; KLENK HD; SULLIVAN NJ; VOLCHKOV VE; FRITZ EA: "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses", NATURE MEDICINE, vol. 11, no. 7, 2005, pages 786 - 90, XP002527152, DOI: doi:10.1038/nm1258
ref_type: npl
severity: background
ref_id: - REGULES JA; BEIGEL JH; PAOLINO KM; VOELL J; CASTELLANO AR; MUNOZ P; MOON JE; RUCK RC; BENNETT JW; TWOMEY PS: "A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report", THE NEW ENGLAND JOURNAL OF MEDICINE, 2015
ref_type: npl
severity: background
ref_id: - HENAO-RESTREPO AM; LONGINI IM; EGGER M; DEAN NE; EDMUNDS WJ; CAMACHO A; CARROLL MW; DOUMBIA M; DRAGUEZ B; DURAFFOUR S: "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial", LANCET, vol. 386, no. 9996, 2015, pages 857 - 66
ref_type: npl
severity: background
ref_id: - AGNANDJI ST; HUTTNER A; ZINSER ME; NJUGUNA P; DAHLKE C; FERNANDES JF; YERLY S; DAYER JA; KRAEHLING V; KASONTA R: "Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report", THE NEW ENGLAND JOURNAL OF MEDICINE, 2015
ref_type: npl
severity: background
ref_id: - BARR JN; WHELAN SP; WERTZ GW: "Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus", BIOCHIM BIOPHYS ACTA, vol. 1577, no. 2, 2002, pages 337 - 53, XP004379211, DOI: doi:10.1016/S0167-4781(02)00462-1
ref_type: npl
severity: background
ref_id: - WERTZ GW; PEREPELITSA VP; BALL LA: "Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 7, 1998, pages 3501 - 6, XP002911691, DOI: doi:10.1073/pnas.95.7.3501
ref_type: npl
severity: background
ref_id: - RABINOVICH S; POWELL RL; LINDSAY RW; YUAN M; CARPOV A; WILSON A; LOPEZ M; COLEMAN JW; WAGNER D; SHARMA P: "A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice", PLOS ONE, vol. 9, no. 9, 2014, pages EL06597
ref_type: npl
severity: background
ref_id: - WITKO SE; JOHNSON JE; KALYAN NK; FELBER BK; PAVLAKIS GN; SIDHU MK; HENDRY RM; UDEM SA; PARKS CL: "Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression", J VIROL METHODS, vol. 164, no. 1-2, 28 November 2009 (2009-11-28), pages 43 - 50, XP026925459, DOI: doi:10.1016/j.jviromet.2009.11.023
ref_type: npl
severity: background
ref_id: - WITKO SE; KOTASH CS; NOWAK RM; JOHNSON JE; BOUTILIER LA; MELVILLE KJ; HERON SG; CLARKE DK; ABRAMOVITZ AS; HENDRY RM: "An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development", J VIROL METHODS, vol. 135, no. 1, 2006, pages 91 - 101, XP025030320, DOI: doi:10.1016/j.jviromet.2006.02.006
ref_type: npl
severity: background
ref_id: - CRONIN J; ZHANG XY; REISER J: "Altering the tropism of lentiviral vectors through pseudotyping", CURRENT GENE THERAPY, vol. 5, no. 4, 2005, pages 387 - 98, XP055199682, DOI: doi:10.2174/1566523054546224
ref_type: npl
severity: background
ref_id: - LEVY C; VERHOEYEN E; COSSET FL: "Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells", CURR OPIN PHARMACOL., vol. 24, 2015, pages 79 - 85, XP029334424, DOI: doi:10.1016/j.coph.2015.08.003
ref_type: npl
severity: background
ref_id: - KAHN JS; ROBERTS A; WEIBEL C; BUONOCORE L; ROSE JK: "Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge", J VIROL., vol. 75, no. 22, 2001, pages 11079 - 87, XP002353198, DOI: doi:10.1128/JVI.75.22.11079-11087.2001
ref_type: npl
severity: background
ref_id: - KAPADIA SU; SIMON ID; ROSE JK: "SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector", VIROLOGY, vol. 376, no. 1, 2008, pages 165 - 72, XP022679026, DOI: doi:10.1016/j.virol.2008.03.002
ref_type: npl
severity: background
ref_id: - FUKAZAWA Y; LUM R; OKOYE AA; PARK H; MATSUDA K; BAE JY; HAGEN SI; SHOEMAKER R; DELEAGE C; LUCERO C: "B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers", NATURE MEDICINE, vol. 21, no. 2, 2015, pages 132 - 9
ref_type: npl
severity: background
ref_id: - FUKAZAWA Y; PARK H; CAMERON MJ; LEFEBVRE F; LUM R; COOMBES N; MAHYARI E; HAGEN SI; BAE JY; REYES MD: "Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines", NATURE MEDICINE, vol. 18, no. 11, 2012, pages 1673 - 81
ref_type: npl
severity: background
ref_id: - SANDERS RW; VAN GILS MJ; DERKING R; SOK D; KETAS TJ; BURGER JA; OZOROWSKI G; CUPO A; SIMONICH C; GOO L: "HIV-1 neutralizing antibodies induced by native-like envelope trimers", SCIENCE, 2015
ref_type: npl
severity: background
ref_id: - SHARMA SK; DE VAL N; BALE S; GUENAGA J; TRAN K; FENG Y; DUBROVSKAYA V; WARD AB; WYATT RT: "Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design", CELL REP., vol. 11, no. 4, 2015, pages 539 - 50, XP055292392, DOI: doi:10.1016/j.celrep.2015.03.047
ref_type: npl
severity: background
ref_id: - BURTON DR; MASCOLA JR: "Antibody responses to envelope glycoproteins in HIV-1 infection", NATURE IMMUNOLOGY, vol. 16, no. 6, 2015, pages 571 - 6
ref_type: npl
severity: background
ref_id: - BLATTNER C; LEE JH; SLIEPEN K; DERKING R; FALKOWSKA E; DE LA PENA AT; CUPO A; JULIEN JP; VAN GILS M; LEE PS: "Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gpl20 Interface on Intact HIV-1 Env Trimers", IMMUNITY, 2014
ref_type: npl
severity: background
ref_id: - FALKOWSKA E; LE KM; RAMOS A; DOORES KJ; LEE JH; BLATTNER C; RAMIREZ A; DERKING R; VAN GILS MJ; LIANG CH: "Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers", IMMUNITY, 2014
ref_type: npl
severity: background
ref_id: - BORITZ E; GERLACH J; JOHNSON JE; ROSE JK: "Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway", J VIROL., vol. 73, no. 8, 10 July 1999 (1999-07-10), pages 6937 - 45, XP002689438
ref_type: npl
severity: background
ref_id: - HOFFENBERG S; POWELL R; CARPOV A; WAGNER D; WILSON A; KOSAKOVSKY POND S; LINDSAY R; ARENDT H; DESTEFANO J; PHOGAT S: "Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes", J VIROL., vol. 87, no. 10, 2013, pages 5372 - 83, XP002711542, DOI: doi:10.1128/JVI.02827-12
ref_type: npl
severity: background
ref_id: - GOO L; CHOHAN V; NDUATI R; OVERBAUGH J: "Early development of broadly neutralizing antibodies in HIV-1-infected infants", NATURE MEDICINE, vol. 20, no. 6, 2014, pages 655 - 8
ref_type: npl
severity: background
ref_id: - WU X; PARAST AB; RICHARDSON BA; NDUATI R; JOHN-STEWART G; MBORI-NGACHA D; RAINWATER SM; OVERBAUGH J: "Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant", J VIROL., vol. 80, no. 2, 2006, pages 835 - 44, XP002711540, DOI: doi:10.1128/JVI.80.2.835-844.2006
ref_type: npl
severity: background
ref_id: - WYATT LS; BELYAKOV IM; EARL PL; BERZOFSKY JA; MOSS B: "Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA", VIROLOGY, vol. 372, no. 2, 1 December 2007 (2007-12-01), pages 260 - 72, XP022496344, DOI: doi:10.1016/j.virol.2007.10.033
ref_type: npl
severity: background
ref_id: - JOHNSON JE; RODGERS W; ROSE JK: "A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions", VIROLOGY, vol. 251, no. 2, 5 December 1998 (1998-12-05), pages 244 - 52, XP026881434, DOI: doi:10.1006/viro.1998.9429
ref_type: npl
severity: background
ref_id: - TANI H; MORIKAWA S; MATSUURA Y: "Development and Applications of VSV Vectors Based on Cell Tropism", FRONT MICROBIOL., vol. 2, 2011, pages 272
ref_type: npl
severity: background
ref_id: - POWELL RL; OUELLETTE I; LINDSAY RW; PARKS CL; KING CR; MCDERMOTT AB; MORROW G: "A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239", BIORESEARCH OPEN ACCESS, vol. 2, no. 3, 2013, pages 171 - 8
ref_type: npl
severity: background
ref_id: - WINSTONE N; WILSON AJ; MORROW G; BOGGIANO C; CHIUCHIOLO MJ; LOPEZ M; KEMELMAN M; GINSBERG AA; MULLEN K; COLEMAN JW: "Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen", J VIROL., vol. 85, no. 18, 8 July 2011 (2011-07-08), pages 9578 - 87
ref_type: npl
severity: background
ref_id: - BAROUCH DH; ALTER G; BROGE T; LINDE C; ACKERMAN ME; BROWN EP; BORDUCCHI EN; SMITH KM; NKOLOLA JP; LIU J: "HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkey", SCIENCE, vol. 349, no. 6245, 2015, pages 320 - 4
ref_type: npl
severity: background
ref_id: - SARZOTTI-KELSOE M; BAILER RT; TURK E; LIN CL; BILSKA M; GREENE KM; GAO H; TODD CA; OZAKI DA; SEAMAN MS: "Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1", J IMMUNOL METHODS, vol. 409, 2014, pages 131 - 46, XP029047122, DOI: doi:10.1016/j.jim.2013.11.022
ref_type: npl
severity: background
ref_id: - UNAIDS, FACT SHEET 2016 UNAIDS, 2016, Retrieved from the Internet <URL:http://www.unaids.org/sites/default/files/media asset/UNAIDS FactSheet en.pdf.>
ref_type: npl
severity: background
ref_id: - T. M. HARMON ET AL.: "Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries", PLOS ONE, vol. 11, 2016, pages E0146387
ref_type: npl
severity: background
ref_id: - M. A. CHECKLEY; B. G. LUTTGE; E. O. FREED: "HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation", JOURNAL OF MOLECULAR BIOLOGY, vol. 410, 2011, pages 582 - 608, XP028380149, DOI: doi:10.1016/j.jmb.2011.04.042
ref_type: npl
severity: background
ref_id: - D. R. BURTON; J. R. MASCOLA: "Antibody responses to envelope glycoproteins in HIV-1 infection", NATURE IMMUNOLOGY, vol. 16, 2015, pages 571 - 576
ref_type: npl
severity: background
ref_id: - P. D. KWONG; J. R. MASCOLA; G. J. NABEL: "Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning", NAT REV IMMUNOL, vol. 13, 2013, pages 693 - 701
ref_type: npl
severity: background
ref_id: - A. B. WARD; I. A. WILSON: "Insights into the trimeric HIV-1 envelope glycoprotein structure", TRENDS BIOCHEM SCI, vol. 40, 2015, pages 101 - 107
ref_type: npl
severity: background
ref_id: - R. J. O'CONNELL; J. H. KIM; L. COREY; N. L. MICHAEL: "Human immunodeficiency virus vaccine trials", COLD SPRING HARB PERSPECT MED, vol. 2, 2012, pages A007351
ref_type: npl
severity: background
ref_id: - J. H. KIM; J. L. EXCLER; N. L. MICHAEL: "Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection", ANNUAL REVIEW OF MEDICINE, vol. 66, 2015, pages 423 - 437
ref_type: npl
severity: background
ref_id: - S. A. PLOTKIN: "Correlates of protection induced by vaccination", CLIN VACCINE IMMUNOL, vol. 11, 2010, pages 1055 - 1065
ref_type: npl
severity: background
ref_id: - C. L. PARKS; L. J. PICKER; C. R. KING: "Development of replication-competent viral vectors for HIV vaccine delivery", CURR OPIN HIV AIDS, vol. 8, 2013, pages 402 - 411, XP055333862, DOI: doi:10.1097/COH.0b013e328363d389
ref_type: npl
severity: background
ref_id: - M. F. BACHMANN; G. T. JENNINGS: "Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns", NAT REV IMMUNOL, vol. 10, 2010, pages 787 - 796, XP055106406, DOI: doi:10.1038/nri2868
ref_type: npl
severity: background
ref_id: - E. BORITZ; J. GERLACH; J. E. JOHNSON; J. K. ROSE: "Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway", J VIROL, vol. 73, 1999, pages 6937 - 6945, XP002689438
ref_type: npl
severity: background
ref_id: - S. M. JONES ET AL.: "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses", NATURE MEDICINE, vol. 11, 2005, pages 786 - 790, XP002527152, DOI: doi:10.1038/nm1258
ref_type: npl
severity: background
ref_id: - A. M. HENAO-RESTREPO ET AL.: "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial", LANCET, vol. 386, 2015, pages 857 - 866
ref_type: npl
severity: background
ref_id: - S. T. AGNANDJI ET AL.: "Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 374, 2016, pages 1647 - 1660
ref_type: npl
severity: background
ref_id: - S. RABINOVICH ET AL.: "A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice", PLOS ONE, vol. 9, 2014, pages EL06597
ref_type: npl
severity: background
ref_id: - E. HASTIE; M. CATALDI; I. MARRIOTT; V. Z. GRDZELISHVILI: "Understanding and altering cell tropism of vesicular stomatitis virus", VIRUS RES, vol. 176, 2013, pages 16 - 32, XP028690314, DOI: doi:10.1016/j.virusres.2013.06.003
ref_type: npl
severity: background
ref_id: - R. W. SANDERS ET AL.: "A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gpl40, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies", PLOSPATHOG, vol. 9, 2013, pages EL003618, XP002769979
ref_type: npl
severity: background
ref_id: - E. FALKOWSKA ET AL.: "Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers", IMMUNITY, 2014
ref_type: npl
severity: background
ref_id: - Y. LI ET AL.: "HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins", J VIROL, vol. 86, 2012, pages 11231 - 11241
ref_type: npl
severity: background
ref_id: - P. L. MOORE ET AL.: "Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1", J VIROL, vol. 80, 2006, pages 2515 - 2528
ref_type: npl
severity: background
ref_id: - F. SALLUSTO; A. LANZAVECCHIA; K. ARAKI; R. AHMED: "From vaccines to memory and back", IMMUNITY, vol. 33, 2010, pages 451 - 463
ref_type: npl
severity: background
ref_id: - J. E. JOHNSON ET AL.: "Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates", VIROLOGY, vol. 360, 2007, pages 36 - 49, XP005907132, DOI: doi:10.1016/j.virol.2006.10.026
ref_type: npl
severity: background
ref_id: - C. SELINGER ET AL.: "Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome", CLIN VACCINE IMMUNOL, vol. 21, 2014, pages 1650 - 1660
ref_type: npl
severity: background
ref_id: - R. R. REGOES: "The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies", PLOS COMPUT BIOL, vol. 8, 2012, pages E 1002767
ref_type: npl
severity: background
ref_id: - M. G. HUDGENS; P. B. GILBERT: "Assessing vaccine effects in repeated low-dose challenge experiments", BIOMETRICS, vol. 65, 2009, pages 1223 - 1232
ref_type: npl
severity: background
ref_id: - D. C. MONTEFIORI: "HIV Protocols", vol. 485, 2009, HUMANA PRESS, pages: 395 - 405
ref_type: npl
severity: background
ref_id: - Y. FUKAZAWA ET AL.: "Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines", NATURE MEDICINE, vol. 18, 2012, pages 1673 - 1681
ref_type: npl
severity: background
ref_id: - B. F. HAYNES ET AL.: "Immune-correlates analysis of an HIV-1 vaccine efficacy trial", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, 2012, pages 1275 - 1286, XP055197181, DOI: doi:10.1056/NEJMoa1113425
ref_type: npl
severity: background
ref_id: - G. D. TOMARAS ET AL.: "Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia", J VIROL, vol. 82, 2008, pages 12449 - 12463, XP008145439, DOI: doi:10.1128/JVI.01708-08
ref_type: npl
severity: background
ref_id: - J. CARTER ET AL.: "Fusion partners can increase the expression of recombinant interleukins via transient transfection in 2936E cells", PROTEIN SCI, vol. 19, 2010, pages 357 - 362, XP055359818, DOI: doi:10.1002/pro.307
ref_type: npl
severity: background
ref_id: - R. GOTTARDO ET AL.: "Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial", PLOS ONE, vol. 8, 2013, pages E75665
ref_type: npl
severity: background
ref_id: - D. H. BAROUCH ET AL.: "Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys", SCIENCE, vol. 349, 2015, pages 320 - 324, XP055359322, DOI: doi:10.1126/science.aab3886
ref_type: npl
severity: background
ref_id: - D. H. BAROUCH ET AL.: "Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys", CELL, vol. 155, 2013, pages 531 - 539, XP028758021, DOI: doi:10.1016/j.cell.2013.09.061
ref_type: npl
severity: background
ref_id: - Q. LI ET AL.: "Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry", J IMMUNOL, vol. 193, 2014, pages 3113 - 3125
ref_type: npl
severity: background
ref_id: - M. SHINGAI ET AL.: "Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques", JEXP MED, vol. 211, 2014, pages 2061 - 2074
ref_type: npl
severity: background
ref_id: - C. J. HENRY DUNAND ET AL.: "Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection", CELL HOST & MICROBE, vol. 19, 2016, pages 800 - 813, XP029594486, DOI: doi:10.1016/j.chom.2016.05.014
ref_type: npl
severity: background
ref_id: - H. M. YASSINE ET AL.: "Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection", NATURE MEDICINE, vol. 21, 2015, pages 1065 - 1070, XP002755796, DOI: doi:10.1038/nm.3927
ref_type: npl
severity: background
ref_id: - M. K. SLIFKA; I. AMANNA: "How advances in immunology provide insight into improving vaccine efficacy", VACCINE, vol. 32, 2014, pages 2948 - 2957, XP028658840, DOI: doi:10.1016/j.vaccine.2014.03.078
ref_type: npl
severity: background
ref_id: - N. HONKE ET AL.: "Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus", NATURE IMMUNOLOGY, vol. 13, 2012, pages 51 - 57
ref_type: npl
severity: background
ref_id: - C. E. MIRE ET AL.: "A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs", J INFECT DIS, vol. 212, 2015, pages 384 - 388
ref_type: npl
severity: background
ref_id: - C. E. MIRE ET AL.: "Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates", PLOS NEGL TROP DIS, vol. 6, 2012, pages E1567
ref_type: npl
severity: background
ref_id: - D. S. LYLES; I. KUZMIN; C. E. RUPPRECHT: "Fields Virology", vol. 1, 2013, LIPPINCOTT WILLIAMS AND WILKINS, pages: 885 - 922
ref_type: npl
severity: background
ref_id: - J. E. JOHNSON; M. J. SCHNELL; L. BUONOCORE; J. K. ROSE: "Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins", J VIROL, vol. 71, 1997, pages 5060 - 5068, XP002969189
ref_type: npl
severity: background
ref_id: - A. DE MILITO: "B lymphocyte dysfunctions in HIV infection", CURR HIV RES, vol. 2, 2004, pages 11 - 21
ref_type: npl
severity: background
ref_id: - S. E. WITKO ET AL.: "An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development", J VIROL METHODS, vol. 135, 2006, pages 91 - 101, XP025030320, DOI: doi:10.1016/j.jviromet.2006.02.006
ref_type: npl
severity: background
ref_id: - P. J. LOPEZ; J. GUILLEREZ; R. SOUSA; M. DREYFUS: "The low processivity of T7 RNA polymerase over the initially transcribed sequence can limit productive initiation in vivo", JOURNAL OF MOLECULAR BIOLOGY, vol. 269, 1997, pages 41 - 51, XP004461417, DOI: doi:10.1006/jmbi.1997.1039
ref_type: npl
severity: background
ref_id: - K. INOUE ET AL.: "An improved method for recovering rabies virus from cloned cDNA", J VIROL METHODS, vol. 107, 2003, pages 229 - 236
ref_type: npl
severity: background
ref_id: - S. HOFFENBERG ET AL.: "Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes", J VIROL, vol. 87, 2013, pages 5372 - 5383, XP002711542, DOI: doi:10.1128/JVI.02827-12
ref_type: npl
severity: background
ref_id: - X. WU ET AL.: "Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant", J VIROL, vol. 80, 2006, pages 835 - 844, XP002711540, DOI: doi:10.1128/JVI.80.2.835-844.2006
ref_type: npl
severity: background
ref_id: - S. K. SHARMA ET AL.: "Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design", CELL REP, vol. 11, 2015, pages 539 - 550, XP055292392, DOI: doi:10.1016/j.celrep.2015.03.047
ref_type: npl
severity: background
ref_id: - P. DE FELIPE ET AL.: "E unum pluribus: multiple proteins from a self-processing polyprotein", TRENDS BIOTECHNOL, vol. 24, 2006, pages 68 - 75, XP025052212, DOI: doi:10.1016/j.tibtech.2005.12.006
ref_type: npl
severity: background
ref_id: - J. J. HANSEN ET AL.: "Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter", HUM GENET, vol. 112, 2003, pages 71 - 77
ref_type: npl
severity: background
ref_id: - N. F. ROSE ET AL.: "An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants", CELL, vol. 106, 2001, pages 539 - 549, XP002297996, DOI: doi:10.1016/S0092-8674(01)00482-2
ref_type: npl
severity: background
ref_id: - A. MORNER ET AL.: "Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage", J VIROL, vol. 73, 1999, pages 2343 - 2349, XP000858398
ref_type: npl
severity: background
ref_id: - P. J. GOULDER; D. I. WATKINS: "Impact of MHC class I diversity on immune control of immunodeficiency virus replication", NAT REV IMMUNOL, vol. 8, 2008, pages 619 - 630
ref_type: npl
severity: background
ref_id: - N. WINSTONE ET AL.: "Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen", J VIROL, vol. 85, 2011, pages 9578 - 9587
ref_type: npl
severity: background
ref_id: - N. L. YATES ET AL.: "Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination", SCI TRANSL MED, vol. 6, 2014, pages 228RA239
ref_type: npl
severity: background
ref_id: - M. WU; P. G. STOCKLEY; W. J. MARTIN: "2nd, An improved western blotting technique effectively reduces background", ELECTROPHORESIS, vol. 23, 2002, pages 2373 - 2376
ref_type: npl
severity: background
ref_id: - T. L. NOLEN; M. G. HUDGENS; P. K. SENB; G. G. KOCH: "Analysis of repeated low-dose challenge studies", STAT MED, vol. 34, 2015, pages 1981 - 1992
ref_type: npl
severity: background
ref_id: - J. E. JOHNSON ET AL.: "In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation", VACCINE, vol. 27, 2009, pages 2930 - 2939, XP026056939, DOI: doi:10.1016/j.vaccine.2009.03.006
ref_type: npl
severity: background
ref_id: - Y. HUANG; P. B. GILBERT; D. C. MONTEFIORI; S. G. SELF: "Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development", STATISTICS IN BIOPHARMACEUTICAL RESEARCH, vol. 1, 2009, pages 81 - 91
ref_type: npl
severity: background
ref_id: - H. X. LIAO ET AL.: "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus", NATURE, vol. 496, 2013, pages 469 - 476, XP055226788, DOI: doi:10.1038/nature12053
ref_type: npl
severity: background
ref_id: - LOVELACE E; XU H; BLISH CA; STRONG R; OVERBAUGH J: "The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization", VIROLOGY, vol. 421, no. 2, 2011, pages 235 - 44, XP028104658, DOI: doi:10.1016/j.virol.2011.09.032
ref_type: npl
severity: background
ref_id: - CHEN J; KOVACS JM; PENG H; RITS-VOLLOCH S; LU J; PARK D ET AL.: "HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein", SCIENCE, vol. 349, no. 6244, 2015, pages 191 - 5
ref_type: npl
severity: background
ref_id: - GE P; TSAO J; SCHEIN S; GREEN TJ; LUO M; ZHOU ZH: "Cryo-EM model of the bullet-shaped vesicular stomatitis virus", SCIENCE, vol. 327, no. 5966, 2010, pages 689 - 93
ref_type: npl
severity: background
ref_id: - NOVELLA IS: "Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution", CURR OPIN MICROBIOL., vol. 6, no. 4, 2003, pages 399 - 405
ref_type: npl
severity: background
ref_id: EP2676676A1
ref_type: patent
severity: background
ref_id: WO2010096678A2
ref_type: patent
severity: background
ref_id: WO2005098009A2
ref_type: patent
severity: background
ref_id: EP2586461A1
ref_type: patent
severity: background
ref_id: US2013095556A1
ref_type: patent
severity: background
ref_id: EP2644701A1
ref_type: patent
severity: background
ref_id: - IVO C. LORENZ ET AL: "The Stem of Vesicular Stomatitis Virus G Can Be Replaced With the HIV-1 Env Membrane-Proximal External Region Without Loss of G Function or Membrane-Proximal External Region Antigenic Properties", AIDS RESEARCH AND HUMAN RETROVIRUSES., vol. 30, no. 11, 1 November 2014 (2014-11-01), US, pages 1130 - 1144, XP055343384, ISSN: 0889-2229, DOI: 10.1089/aid.2013.0206
ref_type: npl
severity: background
ref_id: - D. K. CLARKE ET AL: "Neurovirulence and Immunogenicity of Attenuated Recombinant Vesicular Stomatitis Viruses in Nonhuman Primates", JOURNAL OF VIROLOGY., vol. 88, no. 12, 15 June 2014 (2014-06-15), US, pages 6690 - 6701, XP055343413, ISSN: 0022-538X, DOI: 10.1128/JVI.03441-13
ref_type: npl
severity: background
ref_id: - CHRISTOPHER L PARKS: "DEVELOPMENT OF LIVE VSV VECTORS FOR DELIVERY OF AIDS VACCINES", CONFERENCE-ABSTRACTS-5-2016 - 14TH INTERNATIONAL NEGATIVESTRAND VIRUS MEETING, 2010, BRUGES, BELGIUM, 1 January 2010 (2010-01-01), pages 1 - 1, XP055343796, Retrieved from the Internet <URL:https://www.cavd.org/Lists/ConferenceAbstracts52016/Item/displayifs.aspx?List=9e5a3b2e-18e3-4e00-803e-6f86541df57b&ID=284&ContentTypeId=0x01004F06503D016F9D46AC09606E43BD04B9> [retrieved on 20170208]
ref_type: npl
severity: background
ref_id: - CHRISTOPHER L PARKS ET AL: "DEVELOPMENT OF VSV VECTORS FOR DELIVERY OF ENV IMMUNOGENS", CONFERENCE-ABSTRACTS-5-2016 - AIDS VACCINE 2010; ATLANTA, GA, USA; SEPTEMBER 28 -OCTOBER 01, 2010, 1 January 2010 (2010-01-01), pages 1 - 1, XP055343799, Retrieved from the Internet <URL:https://www.cavd.org/Lists/ConferenceAbstracts52016/Item/displayifs.aspx?List=9e5a3b2e-18e3-4e00-803e-6f86541df57b&ID=285&ContentTypeId=0x01004F06503D016F9D46AC09606E43BD04B9> [retrieved on 20170208]
ref_type: npl
severity: background
ref_id: - CHRISTOPHER L. PARKS ET AL: "Development of replication-competent viral vectors for HIV vaccine delivery", CURRENT OPINION IN HIV AND AIDS, vol. 8, no. 5, 1 September 2013 (2013-09-01), US, pages 402 - 411, XP055333862, ISSN: 1746-630X, DOI: 10.1097/COH.0b013e328363d389
ref_type: npl
severity: background
ref_id: - CL PARKS ET AL: "Viral vector delivery of Env trimer immunogens", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. Suppl 2, 13 September 2012 (2012-09-13), pages P341, XP021116582, ISSN: 1742-4690, DOI: 10.1186/1742-4690-9-S2-P341
ref_type: npl
severity: background
ref_id: - KJ WRIGHT ET AL: "Optimizing expression of functional HIV envelopes in rVSV-[Delta]G vaccine vec", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. Suppl 2, 13 September 2012 (2012-09-13), pages P342, XP021116583, ISSN: 1742-4690, DOI: 10.1186/1742-4690-9-S2-P342
ref_type: npl
severity: background
ref_id: EP2568289A2
ref_type: patent
severity: background
ref_id: - STEFAN H. STRICKER ET AL: "P-GAP-43 Is Enriched in Horizontal Cell Divisions throughout Rat Cortical Development", CEREBRAL CORTEX, vol. 16, no. suppl_1, 1 July 2006 (2006-07-01), GB, pages i121 - i131, XP055483815, ISSN: 1047-3211, DOI: 10.1093/cercor/bhj171
ref_type: npl
severity: background
ref_id: - SIMON HOFFENBERG ET AL: "Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 87, no. 10, 1 May 2013 (2013-05-01), pages 5372 - 5383, XP002711542, ISSN: 0022-538X, [retrieved on 20130306], DOI: 10.1128/JVI.02827-12
ref_type: npl
severity: background
ref_id: - ULLA WEWER ET AL: "Human Laminin Isolated in a Nearly Intact, Biologically Active Form from Placenta by Limited Proteolysis*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 25 October 1983 (1983-10-25), USA, pages 12654 - 12660, XP055174073, Retrieved from the Internet <URL:http://www.jbc.org/content/258/20/12654.full.pdf> [retrieved on 20150305]
ref_type: npl
severity: background
ref_id: WO2005098009
ref_type: patent
severity: background
ref_id: WO2010096678
ref_type: patent
severity: novelty_destroying
ref_id: US2013095556
ref_type: patent
severity: background
ref_id: EP2586461
ref_type: patent
severity: background
ref_id: EP2644701
ref_type: patent
severity: background
ref_id: EP2676676
ref_type: patent
severity: novelty_destroying
ref_id: - IVO C. LORENZ ET AL, "The Stem of Vesicular Stomatitis Virus G Can Be Replaced With the HIV-1 Env Membrane-Proximal External Region Without Loss of G Function or Membrane-Proximal External Region Antigenic Properties", AIDS RESEARCH AND HUMAN RETROVIRUSES., US, (20141101), vol. 30, no. 11, doi:10.1089/aid.2013.0206, ISSN 0889-2229, pages 1130 - 1144, XP055343384 [A] 1-19
ref_type: npl
severity: background
ref_id: - D. K. CLARKE ET AL, "Neurovirulence and Immunogenicity of Attenuated Recombinant Vesicular Stomatitis Viruses in Nonhuman Primates", JOURNAL OF VIROLOGY., US, (20140615), vol. 88, no. 12, doi:10.1128/JVI.03441-13, ISSN 0022-538X, pages 6690 - 6701, XP055343413 [A] 1-19
ref_type: npl
severity: background
ref_id: - Christopher L Parks, "DEVELOPMENT OF LIVE VSV VECTORS FOR DELIVERY OF AIDS VACCINES", Conference-Abstracts-5-2016 - 14th International NegativeStrand Virus Meeting, 2010, Bruges, Belgium, (20100101), pages 1 - 1, URL: https://www.cavd.org/Lists/ConferenceAbstracts52016/Item/displayifs.aspx?List=9e5a3b2e-18e3-4e00-803e-6f86541df57b&ID=284&ContentTypeId=0x01004F06503D016F9D46AC09606E43BD04B9, (20170208), XP055343796 [A] 1-19
ref_type: npl
severity: background
ref_id: - Christopher L Parks ET AL, "DEVELOPMENT OF VSV VECTORS FOR DELIVERY OF ENV IMMUNOGENS", Conference-Abstracts-5-2016 - AIDS Vaccine 2010; Atlanta, GA, USA; September 28 -October 01, 2010, (20100101), pages 1 - 1, URL: https://www.cavd.org/Lists/ConferenceAbstracts52016/Item/displayifs.aspx?List=9e5a3b2e-18e3-4e00-803e-6f86541df57b&ID=285&ContentTypeId=0x01004F06503D016F9D46AC09606E43BD04B9, (20170208), XP055343799 [A] 1-19
ref_type: npl
severity: background
ref_id: - CHRISTOPHER L. PARKS ET AL, "Development of replication-competent viral vectors for HIV vaccine delivery", CURRENT OPINION IN HIV AND AIDS, US, (20130901), vol. 8, no. 5, doi:10.1097/COH.0b013e328363d389, ISSN 1746-630X, pages 402 - 411, XP055333862 [A] 1-19
ref_type: npl
severity: background
ref_id: - CL PARKS ET AL, "Viral vector delivery of Env trimer immunogens", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, (20120913), vol. 9, no. Suppl 2, doi:10.1186/1742-4690-9-S2-P341, ISSN 1742-4690, page P341, XP021116582 [A] 1-19
ref_type: npl
severity: background
ref_id: - KJ WRIGHT ET AL, "Optimizing expression of functional HIV envelopes in rVSV-[Delta]G vaccine vec", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, (20120913), vol. 9, no. Suppl 2, doi:10.1186/1742-4690-9-S2-P342, ISSN 1742-4690, page P342, XP021116583 [A] 1-19
ref_type: npl
severity: background
Final disposition: pending (2017-04-05)